Skip to main content
Have a personal or library account? Click to login
Fatal Fulminant Myocarditis Following a Single Dose of Pembrolizumab in a Patient with Recurrent Thymoma: A Case Report Cover

Fatal Fulminant Myocarditis Following a Single Dose of Pembrolizumab in a Patient with Recurrent Thymoma: A Case Report

Forum of Clinical Oncology
AHEAD OF PRINT
By: ,   and    
Open Access
|May 2026
Figures & tables

Figures & Tables

Figure 1:

Histological section of thymoma demonstrating lobular architecture with cellular lobules intersected by sharply demarcated fibrocollagenous bands (H&E stain, 40× magnification).

Figure 2:

Histological section of thymoma showing characteristic histomorphology with neoplastic polygonal epithelial cells and abundant thymocytes (H&E stain, 40× magnification).

Figure 3:

Histological section of thymoma demonstrating lobular architecture with cellular lobules separated by fibrous bands (H&E stain, 10× magnification).

Figure 4:

ECG of the patient showing diffuse ST-T elevation.
DOI: https://doi.org/10.2478/fco-2024-0025 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Submitted on: Aug 17, 2025
Accepted on: Nov 3, 2025
Published on: May 21, 2026
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Thymoma,
immune checkpoint inhibitors,
pembrolizumab,
myocarditis,
immune-related adverse events,
PD-L1
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2026 Marwa Haitham Al-Najafi, Rasha Raed Al-Mallah, Nazar Mohammed Ther Jawhar, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT